Highly specific quantification of ergotamine in urine, blood, and hair samples by liquid chromatography-tandem mass spectrometry

Therapeutic Drug Monitoring

Volumn 29, Issue 3, 2007, Pages 325-332

  Favretto, Donata ^a   Frison, Giampietro ^a   Vogliardi, Susanna ^a   Ferrara, Santo Davide ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Biofluids; Ergotamine; Hair; Iatrogenic ergotism; Tandem mass spectrometry

Indexed keywords

CAFERGOT; ERGOTAMINE; LYSERGIC ACID; LYSERGIDE; NIFEDIPINE; VASOCONSTRICTOR AGENT;

ADULT; ANGIOGRAPHY; ARTICLE; BLOOD SAMPLING; CASE REPORT; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; ERGOTISM; FEMALE; FRAGMENTATION REACTION; HAIR ANALYSIS; HEADACHE; HUMAN; HYDRATION; IATROGENIC DISEASE; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; POSITIVE ION ELECTROSPRAY; PRIORITY JOURNAL; STENOSIS; TANDEM MASS SPECTROMETRY; URINALYSIS; BLOOD; CHEMISTRY; CLINICAL TRIAL; HAIR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PATHOPHYSIOLOGY; URINE;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; ERGOTAMINE; ERGOTISM; FEMALE; HAIR; HUMANS; TANDEM MASS SPECTROMETRY; VASOCONSTRICTOR AGENTS;

EID: 34447509206     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318067dfe7     Document Type: Article

References (37)

1. Barger G. Ergot and ergotism. London: Gurney and Jackson; 1931.
2. Eadie MJ. Convulsive ergotism: epidemics of the serotonin syndrome? Lancet Neurol. 2003;2:429-434.
3. Stoll A. Kenntniss der Mutterkornalkaloide. Veeh Dtsch Schweiz Naturf Ges. 1920;101:190.
4. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997;37:S15-S25.
5. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43:144-166.
6. Ala-Hurula V, Myllyla VV, Arvela P, et al. Systemic availability of ergotamine tartrate after three successive doses and during continuous medication. Eur J Clin Pharmacol. 1979;16:355-360.
7. Tfelt-Hansen P, Paalzow L. Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther. 1985;37:29-35.
8. Matthews NT, Havill JH. Ergotism with therapeutic doses of ergotamine tartrate. N Z Med J. 1979;89:476-477.
9. Aellig WH, Nüesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. Int J Clin Pharmacol Biopharm. 1977;15:106-112.
10. Ala-Hurula V, Myllyla VV, Arvela P, et al. Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. Eur J Clin Pharmacol. 1979;15:51-55.
11. Hovdal H, Syversen GB, Rosenthaler J. Ergotamine in plasma and CSF after i.m. and rectal administration to humans. Cephalalgia. 1982;2:145-150.
12. Ala-Hurula V. Correlation between pharmacokinetics and clinical effects of ergotamine in patients suffering from migraine. Eur J Clin Pharmacol. 1982;21:397-402.
13. Rosenthaler J, Munzer H, Voges R, et al. Immunoassay of ergotamine and dihydroergotamine using a common 3H-labelled ligand as tracer for specific antibody and means to overcome experienced pitfalls. Int J Nucl Med Biol. 1984;11:85-89.
14. Edlund PO. Determination of ergot alkaloids in plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr. 1981;226:107-115.
15. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers. Eur J Clin Pharmacol. 1982;23:235-240.
16. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Linear pharmacokinetics of intravenous ergotamine tartrate. Eur J Clin Pharmacol. 1985;29:61-66.
17. Haering N, Settlage JA, Sanders SW, et al. Measurement of ergotamine in human plasma by triple sector quadrupole mass spectrometry with negative ion chemical ionization. Biomed Mass Spectrom. 1985;12:197-199.
18. Sanders SW, Haering N, Mosberg H, et al. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol. 1986;30:331-334.
19. Feng N, Minder EI, Grampp T, et al. Identification and quantification of ergotamine in human plasma by gas chromatography-mass spectrometry. J Chromatogr. 1992;575:289-294.
20. Casy AF. Mass spectrometry as an aid to the identification of ergots and dihydroergots: comparison of hard and soft ionization techniques. J Pharm Biomed Anal. 1994;12:41-46.
21. Johansen SS, Karkov J. A fatal overdose of the ergot derivative cabergoline. Forensic Science Int. 2004;146:47-51.
22. Hughes N, Winnik W, Dunyach JJ, et al. High-sensitivity quantitation of cabergoline and pergolide using a triple-quadrupole mass spectrometer with enhanced mass-resolution capabilities. J Mass Spectrom. 2003;38:743-751.
23. Friedrich G, Appel K, Rose T, et al. Determination of dihydroergocryptine in human plasma and urine samples using on-line sample extraction-column- switching reversed-phase liquid chromatography-mass spectrometry. J Chromatogr B. 2004;808:131-139.
24. Igarashi K, Hotta K, Kasuya F, et al. Determination of cabergoline and L-dopa in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2003;792:55-61.
25. Salvador A, Dubreuil D, Denouel J, et al. Sensitive method for the quantitative determination of bromocriptine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B. 2005;820:237-242.
26. Favretto D, Frison G, Maietti S, et al. LC-ESI-MS/MS on an ion trap for the determination of LSD, iso-LSD, nor-LSD and 2-oxo-3-hydroxy-LSD in blood, urine and vitreous humor. Int J Legal Med. Published on line February 23, 2006. www.springerlink.com/content/c37k71pxp400255h/.
27. Lehner AF, Craig M, Fannin N, et al. Electrospray[+] tandem quadrupole mass spectrometry in the elucidation of ergot alkaloids chromatographed by HPLC: screening of grass or forage samples for novel toxic compounds. J Mass Spectrom. 2005;40:1484-1502.
28. Lehner AF, Craig M, Fannin N, et al. Fragmentation patterns of selected ergot alkaloids by electrospray ionization tandem quadrupole mass spectrometry. J Mass Spectrom. 2004;39:1275-1286.
29. Mohamed R, Gremaud E, Tabet JC, et al. Mass spectral characterization of ergot alkaloids by electrospray ionization, hydrogen/deuterium exchange, and tandem mass spectrometry: usefulness of precursor ion scan experiments. Rapid Commun Mass Spectrom. 2006;20:2787-2799.
30. Palombo D, Mirelli M, Peinetti F, et al. Spasm of arm arteries due to ergotamine tartrate: a case report. Int Angiol. 1991;10:51-53.
31. Wells KE, Steed DL, Zajko AB, et al. Recognition and treatment of arterial insufficiency from cafergot. J Vasc Surg. 1986;4:8-15.
32. Jones NS, Lewis LD. Ergotamine-induced peripheral ischemia reversed by oral thymoxamine hydrochloride. Hum Toxicol. 1986;5:61-62.
33. Ausband SC, Goodman PE. An unusual case of clarithromycin associated ergotism. J Emerg Med. 2001;21:411-413.
34. Gabelica V, De Pauw E. Internal energy and fragmentation of ions produced in electrospray sources. Mass Spectrom Rev. 2005;24:566-587.
35. Kebarle P. A brief overview of the present status of the mechanisms involved in electrospray mass spectrometry. J Mass Spectrom. 2000;35:804-817.
36. Komarova EL, Tolkachev ON. The chemistry of peptide ergot alkaloids. Part 1: classification and chemistry of ergot peptides. Pharm Chem J. 2001;35:504-513.
37. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta. 2006;370:17-49.